Literature DB >> 23052373

Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9).

Jorunn Litlekalsoy1, Jens G Hostmark, Daniela Elena Costea, Martin Illemann, Ole Didrik Laerum.   

Abstract

The aim of this study was to evaluate changes and correlations between various molecular markers related to growth regulation and invasiveness in urothelial carcinomas in samples collected from 1932 to 2004. Paraffin-embedded autopsy/biopsy tissues from 144 patients were stained with antibodies against H-K-N ras proteins, pTEN protein, urokinase plasminogen activator receptor (uPAR), plasminogen activator inhibitor-1 (PAI-1) and matrix metalloproteinase-9 (MMP-9) and analyzed by in situ hybridization. Statistical analysis was performed by SPSS using cross tabulation and logistic regression. While the presence of K-ras, N-ras, PAI-1, and loss of pTEN increased over the last few decades, uPAR expression decreased during the same period. The increase in K-ras expression associated positively with the increase in expression of the other two ras proteins, H-ras and N-ras, and the loss of pTEN. A strong positive correlation was also observed between PAI-1 and uPAR, PAI-1 and previously detected markers, EGFR (epidermal growth factor receptor) and p53. Presence of uPAR was found to be positively associated with p16 expression. Multivariate analysis with clinical parameters revealed a positive correlation between PAI-1 expression and tumour grade, CkHMW (high molecular weight cytokeratin) and tumour grade, CkHMW and metastasis, EGFR and metastasis. mRNA could be detected in samples from the last 50 years while older samples were negative, indicating its complete degradation during longer storage. In conclusion, increased accumulation of K-ras, N-ras, and PAI-1 together with loss of pTEN in bladder carcinomas of grades II and III seems to be more dominant in recent times, suggesting an altered malignant potential in these neoplasms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052373     DOI: 10.1007/s00428-012-1323-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  21 in total

Review 1.  The role of the plasminogen activation system in cancer.

Authors:  V A Carroll; B R Binder
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

Review 2.  Bladder cancer epidemiology.

Authors:  G M Matanoski; E A Elliott
Journal:  Epidemiol Rev       Date:  1981       Impact factor: 6.222

3.  H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers.

Authors:  B Przybojewska; A Jagiello; P Jalmuzna
Journal:  Cancer Genet Cytogenet       Date:  2000-08

4.  Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

Authors:  Shahrokh F Shariat; Alexandre R Zlotta; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Journal:  Mod Pathol       Date:  2007-03-02       Impact factor: 7.842

Review 5.  New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.

Authors:  J M Cherrington; L M Strawn; L K Shawver
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

6.  Immunohistochemical biomarkers for bladder cancer prognosis.

Authors:  Kazuhito Matsushita; Eugene K Cha; Kazumasa Matsumoto; Shiro Baba; Thomas F Chromecki; Harun Fajkovic; Maxine Sun; Pierre I Karakiewicz; Douglas S Scherr; Shahrokh F Shariat
Journal:  Int J Urol       Date:  2011-07-20       Impact factor: 3.369

7.  Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors.

Authors:  D Vageli; H Kiaris; D Delakas; P Anezinis; A Cranidis; D A Spandidos
Journal:  Cancer Lett       Date:  1996-10-22       Impact factor: 8.679

8.  Declining mortality from bladder cancer in Europe.

Authors:  Jacques Ferlay; Giorgia Randi; Cristina Bosetti; Fabio Levi; Eva Negri; Peter Boyle; Carlo La Vecchia
Journal:  BJU Int       Date:  2007-10-30       Impact factor: 5.588

9.  K-RAS mutation in transitional cell carcinoma of urinary bladder.

Authors:  S Ayan; G Gokce; H Kilicarslan; O Ozdemir; E Yildiz; E Y Gultekin
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

10.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

View more
  1 in total

1.  Expression of circadian clock genes and proteins in urothelial cancer is related to cancer-associated genes.

Authors:  Jorunn Litlekalsoy; Kari Rostad; Karl-Henning Kalland; Jens G Hostmark; Ole Didrik Laerum
Journal:  BMC Cancer       Date:  2016-07-27       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.